|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings indicate that FOXD1 promotes tumorgenesis and progression of CRC by activating ERK 1/2 signaling pathway and may represent a potential clinical target.
|
29887965 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of FOXD1 attenuated CRC cell proliferation, migration and invasion.
|
29887965 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
FOXD1 predicts prognosis of colorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway.
|
29887965 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, its expression pattern in colorectal cancer (CRC) and the molecular mechanism of FOXD1 on cancer progression remain unknown.
|
29887965 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that FOXD1 was aberrantly overexpressed in human CRC tissues, and FOXD1 levels were correlated with tumor size, differentiation, TNM stage and lymph node metastasis and poor prognosis.
|
29887965 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In vivo assay further showed the inhibition of tumor growth after knockdown of FOXD1.
|
29936179 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In vitro assay showed that inhibitior of FOXD1 suppressed cell proliferation, migration and invasion in MG63 and U2OS cells, while overexpression of FOXD1 promoted OS cell proliferation and migration.
|
29936179 |
2018 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggested that FOXD1 might play key roles in OS development and progression, and was negatively regulated by miR-30a-5p in OS.
|
29936179 |
2018 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggested that FOXD1 might play key roles in OS development and progression, and was negatively regulated by miR-30a-5p in OS.
|
29936179 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggested that FOXD1 might play key roles in OS development and progression, and was negatively regulated by miR-30a-5p in OS.
|
29936179 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Molecular, structural, and functional aspects of FOXD1 are presented in light of physiological and pathogenic conditions, including its role in human disease aetiology, such as cancer and recurrent pregnancy loss.
|
29959475 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Molecular, structural, and functional aspects of FOXD1 are presented in light of physiological and pathogenic conditions, including its role in human disease aetiology, such as cancer and recurrent pregnancy loss.
|
29959475 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We conclude that FOXD1 may influence invasion and migration via indirect regulation of MMP9 and RAC1B alternative splicing in melanoma cells.
|
30110134 |
2018 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our study, we show that the neural crest-associated transcription factor FOXD1 plays a key role in the invasion and the migration capacities of metastatic melanomas both in vivo and in vitro.
|
30110134 |
2018 |
|
Hereditary pancreatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we report that loss of the tumor suppressor gene Tsc2 in pericytes using a FoxD1 promoter driven cre allele (Foxd1tm1(GFP/cre) Amc, FoxD1GC) leads to the formation of HPC in multiple sites.
|
30124871 |
2018 |
|
Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
FOXD1 was identified as the up-regulated gene in glioma based on microarray data of GSE65626.
|
30225541 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.
|
30225541 |
2018 |
|
Renal fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Autophagy in FOXD1 stroma-derived cells regulates renal fibrosis through TGF-β and NLRP3 inflammasome pathway.
|
30545632 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The functional roles of FOXD1 in NSCLC were demonstrated cell viability CCK-8 assay, colony formation, cell invasion and migration assays, and cell apoptosis assay in vitro.
|
30562753 |
2018 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
FOXD1 Promotes Cell Growth and Metastasis by Activation of Vimentin in NSCLC.
|
30562753 |
2018 |
|
Intestinal metaplasia of gastric mucosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
Suppression of miR-92a-1-5p and restoration of FOXD1 may be a preventive approach for gastric IM in patients with bile regurgitation.
|
30635407 |
2019 |
|
Regurgitation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Suppression of miR-92a-1-5p and restoration of FOXD1 may be a preventive approach for gastric IM in patients with bile regurgitation.
|
30635407 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
|
30792394 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
|
30792394 |
2019 |
|
Tumor Angiogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.
|
30792394 |
2019 |